{"product_id":"bioclinic-pea-90vcaps","title":"BioClinic-PEA - 90vcaps","description":"\u003cmeta charset=\"utf-8\"\u003e\n\u003cdiv class=\"uses_benefits\"\u003e\n\u003ch3\u003eBenefits\u003c\/h3\u003e\n\u003cul class=\"feature-list\"\u003e\n\u003cli\u003eFor chronic pain relief\u003c\/li\u003e\n\u003cli\u003eOffers a natural source of PEA from non-GMO saffl ower oil\u003c\/li\u003e\n\u003cli\u003eMicronized for improved bioavailability\u003c\/li\u003e\n\u003cli\u003eProvides 400 mg PEA in each capsule, allowing for easyand clinically relevant dosing\u003c\/li\u003e\n\u003cli\u003eSuitable for vegetarians and vegans\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"feature_summary\"\u003e\n\u003ch3\u003eFeature Summary\u003c\/h3\u003e\n\u003cp\u003ePalmitoylethanolamide (PEA) is an endogenously produced lipid that mediates the resolution of neuroinflammation and clinically reduces pain from a variety of sources.\u003csup\u003e1,2,3\u003cspan\u003e \u003c\/span\u003e\u003c\/sup\u003ePEA is a type of fatty acid ethanolamine produced in microglia and mast cells, where it downregulates the activation of both cell types; levels of PEA are increased in brain areas involved in nociception, and appear to modulate protective responses to both inflammation and pain.\u003csup\u003e4\u003c\/sup\u003e\u003cspan\u003e \u003c\/span\u003eIts effects are mediated via direct activation of PPAR-a and GPR55 receptors, and potentially by indirect activation of CB1 and CB2 receptors and the TRPV1 channel (i.e., the capsaicin receptor).\u003csup\u003e5,6\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp\u003eIn clinical trials, PEA has been shown to reduce pain levels from a variety of chronic conditions (of at least 6 months duration) where pain was not controlled by standard therapies, demonstrating effectiveness both alone and when combined with standard treatments.\u003csup\u003e7\u003c\/sup\u003e\u003cspan\u003e \u003c\/span\u003ePEA has been shown to be efficacious for pain resulting from nerve compression syndromes, including sciatica and carpal tunnel syndrome.\u003csup\u003e8\u003c\/sup\u003e\u003cspan\u003e \u003c\/span\u003eRandomized trials have also shown benefit for pain control for specific conditions, including TMJ,\u003csup\u003e9\u003c\/sup\u003e\u003cspan\u003e \u003c\/span\u003eas well as for depressive symptoms in major depressive disorder when used in conjunction with antidepressants.\u003csup\u003e10\u003c\/sup\u003e\u003cspan\u003e \u003c\/span\u003eIn addition, PEA has been shown to improve endothelial function and reduce intraocular pressure among patients with ocular hypertension.\u003csup\u003e11,12\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003c\/sup\u003e\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003eSkaper, S.D., Facci, L., Barbierato, M., et al. (2015). N-Palmitoylethanolamine and neuroinflammation: a novel therapeutic strategy of resolution.\u003ci\u003e\u003cspan\u003e \u003c\/span\u003eMolecular Neurobiology, 52(\u003c\/i\u003e2),1034–1042. PMID: 26055231\u003c\/li\u003e\n\u003cli\u003eArtukoglu, B.B., Beyer, C., Zuloff-Shani, A., et al. (2017). Efficacy of palmitoylethanolamide for pain: a meta-analysis.\u003cspan\u003e \u003c\/span\u003e\u003ci\u003ePain Physician, 20(\u003c\/i\u003e5), 353–362. PMID: 28727699\u003c\/li\u003e\n\u003cli\u003ePaladini, A., Fusco, M., Cenacchi, T., et al. (2016). Palmitoylethanolamide, a special food for medical purposes, in the treatment of chronic pain: a pooled data meta-analysis.\u003cspan\u003e \u003c\/span\u003e\u003ci\u003ePain Physician, 19(\u003c\/i\u003e2), 11–24. PMID: 26815246\u003c\/li\u003e\n\u003cli\u003eSkaper, S.D., Facci, L., et al. (2012). Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide.\u003cspan\u003e \u003c\/span\u003e\u003ci\u003ePhilosophical Transactions of the Royal Society of London Series B, Biological Sciences, 367(\u003c\/i\u003e1607), 3312–3325. PMID: 23108549\u003c\/li\u003e\n\u003cli\u003eRinne, P., Guillamat-Prats, R., Rami, M., et al. (2018). Palmitoylethanolamide promotes a proresolving macrophage phenotype and attenuates atherosclerotic plaque formation.\u003cspan\u003e \u003c\/span\u003e\u003ci\u003eArteriosclerosis, Thrombosis, and Vascular Biology, 38(\u003c\/i\u003e11), 2562–2575. PMID: 30354245\u003c\/li\u003e\n\u003cli\u003ePetrosino, S.\u0026amp; Di Marzo, V. (2017). The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations.\u003cspan\u003e \u003c\/span\u003e\u003ci\u003eBritish Journal of Pharmacology, 174(\u003c\/i\u003e11), 1349–1365. PMID: 27539936\u003c\/li\u003e\n\u003cli\u003eGatti, A., Lazzari, M., et al. (2012). Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogenesis.\u003cspan\u003e \u003c\/span\u003e\u003ci\u003ePain Medicine, 13(\u003c\/i\u003e9), 1121–1130. PMID: 22845893\u003c\/li\u003e\n\u003cli\u003eKeppel Hesselink, J.M. \u0026amp; Kopsky, D.J. (2015). Palmitoylethanolamide, a neutraceutical, in nerve compression syndromes: efficacy and safety in sciatic pain and carpal tunnel syndrome.\u003cspan\u003e \u003c\/span\u003e\u003ci\u003eJournal of Pain Research, 8,\u003c\/i\u003e\u003cspan\u003e \u003c\/span\u003e729–734. PMID: 26604814\u003c\/li\u003e\n\u003cli\u003eMarini, I., Bartolucci, M.L., et al. (2012). Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain.\u003cspan\u003e \u003c\/span\u003e\u003ci\u003eJournal of Orofacial Pain, 26(\u003c\/i\u003e2), 99–104. PMID: 22558609\u003c\/li\u003e\n\u003cli\u003eGhazizadeh-Hashemi, M., Ghajar, A., et al. (2018). Palmitoylethanolamide as adjunctive therapy in major depressive disorder: A double-blind, randomized and placebo-controlled trial.\u003cspan\u003e \u003c\/span\u003e\u003ci\u003eJournal of Affective Disorders, 232,\u003cspan\u003e \u003c\/span\u003e\u003c\/i\u003e127–133. PMID: 29486338\u003c\/li\u003e\n\u003cli\u003eStrobbe, E., Cellini, M., \u0026amp; Campos, E.C. (2013). Effectiveness of palmitoylethanolamide on endothelial dysfunction in ocular hypertensive patients: a randomized, placebo-controlled cross-over study.\u003ci\u003e\u003cspan\u003e \u003c\/span\u003eInvestigative Ophthalmology \u0026amp; Vision Science, 54(\u003c\/i\u003e2), 968–973. PMID: 23307959\u003c\/li\u003e\n\u003cli\u003eGagliano, C., Ortisi, E., Pulvirenti, L., et al. (2011). Ocular hypotensive effect of oral palmitoyl-ethanolamide: a clinical trial.\u003ci\u003e\u003cspan\u003e \u003c\/span\u003eInvestigative Ophthalmology \u0026amp; Vision Science, 52(\u003c\/i\u003e9), 6096–6100. PMID: 21705689\u003c\/li\u003e\n\u003cli\u003eNestmann, E.R. (2016). Safety of micronized palmitoylethanolamide (microPEA): lack of toxicity and genotoxic potential.\u003ci\u003e\u003cspan\u003e \u003c\/span\u003eFood Science Nutrition, 5(\u003c\/i\u003e2), 292–309. PMID: 28265364\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003csup\u003e\u003cbr\u003e\u003c\/sup\u003e\u003c\/p\u003e\n\u003c\/div\u003e","brand":"BioClinic Naturals","offers":[{"title":"Default Title","offer_id":45900240945436,"sku":"AN-9331","price":54.56,"currency_code":"CAD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0739\/9733\/files\/BioClinic-PEA---90vcaps.jpg?v=1690477286","url":"https:\/\/store.whitelotusclinic.ca\/products\/bioclinic-pea-90vcaps","provider":"White Lotus Clinic","version":"1.0","type":"link"}